Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01959698
Title Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

diffuse large B-cell lymphoma

Therapies

Carfilzomib + Rituximab

Carboplatin + Etoposide + Ifosfamide

Age Groups: adult
Covered Countries USA


No variant requirements are available.